'Pharma Bro' Shkreli released to halfway house in US / Photo: SPENCER PLATT - GETTY IMAGES NORTH AMERICA/AFP/File
-
Microsoft Updates Xbox PC App with 60% Faster Startup and Redesigned Interface
-
Cause of Death Revealed for 'Ellen' Producer Matthew Wright
-
Early Polar Vortex Disruption Creates Uncertain Winter Outlook for Pennsylvania
-
Edmund Richardson Wins Baillie Gifford Prize for 'Alexander' Biography
-
Pakistan Demands Grant-Based Climate Finance at COP31 to Avoid Debt Trap
-
BYD Drops Rotating Screens in New Models Due to Tech Limits
-
E Pellicci Pop-Up at Selfridges Brings Back Nostalgic School Cake
-
Ryanair Flight from Rome Makes Emergency Landing in Lisbon After Bomb Threat
-
Coronation Street's Debbie Webster Steps Down as Dementia Storyline Intensifies
'Pharma Bro' Shkreli released to halfway house in US
So-called "Pharma bro" Martin Shkreli has been released from a Pennsylvania prison to a halfway house in New York state, the US Bureau of Prisons said Wednesday.
Shkreli, who became a poster child for predatory pharmaceutical pricing before being convicted of securities fraud in 2017, was transferred Wednesday from a low-security prison in Allenwood, Pennsylvania to undisclosed "community confinement" in New York state, said a BOP spokesperson in an email.
He is scheduled to be released from BOP's custody on September 14, the spokesperson said.
Shkreli's attorney, Benjamin Brafman, confirmed the release, saying he was "pleased" to report that his client was let out early "after completing all programs that allowed for his prison sentence to be shortened," according to a statement.
"While in the halfway house I have encouraged Mr. Shkreli to make no further statement, nor will he or I have any additional comments at this time."
Once dubbed "the most hated man in America," Shkreli, 39, became infamous for suddenly raising the price of the HIV drug Daraprim in 2015 by 5,000 percent -- from $13.50 a pill to $750.
Shkreli was originally sentenced in 2018 to seven years in prison in a fraud case not directly related to the Daraprim matter. He has been in custody since September 2017.
A.Mahlangu--AMWN
